- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04871477
Adoption of Audio Recording in the Outpatient Supportive Care Center
The Adoption of Audio Recording in the Outpatient Supportive Care Center
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To assess the patient's perception of the usefulness of the audio recording in helping to recall information given to him/her in the visit along with the perception of usefulness in the dissemination of information to family member(s) and/or caregiver(s) not present at the clinic visit.
SECONDARY OBJECTIVES:
I. To assess the number of times the recording is listened to. II. To assess the ease of use of the technology. III. To assess the ability to share the information with the patient's family member(s) and/or caregiver(s) if he or she chooses to do so.
IV. To assess the patient perception of whether the audio recording caused any disruption to the clinic.
V. To estimate the participation rate of patients. VI. To explore association between patient's perception of the usefulness of the audio recording and patient's demographic/clinical characteristics.
VII. To explore the association between age and sex of the caregiver and frequency of caregiver's use of the audio recording.
VIII. To explore the association of the ease of use of the technology and the type of device and application used.
OUTLINE:
Patients audio record the recommendations and instructions given to them by the doctor record as part of their clinic visit at the Supportive Care Center.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
Contact:
- Michael J. Tang
- Phone Number: 713-792-6085
- Email: ctang1@mdanderson.org
-
Principal Investigator:
- Michael J. Tang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with the diagnosis of advanced cancer as defined as locally advanced, recurrent or metastatic cancer. Both solid and liquid tumors are eligible for the study
- Patients who are seen in the outpatient supportive care center at M.D. Anderson Cancer Center
- Patients who have access to a recording device or cellphone with recording technology
- Patients who can be contacted 7 to 11 days from the clinic visit that the recording took place
- Patients who can sign informed consent
- Patients who are able to read and write in English
- Patients 18 years or older
Exclusion Criteria:
- Patients who have been diagnosed with delirium or cognitive impairment. This will be defined by chart review along with review of the MD Anderson Symptom Inventory (MDAS) the day of clinic visit. An MDAS of 7 or greater will be considered to define delirium in this study
- Patients who are unwilling to sign informed consent
- Patients who have used audio recordings before in clinic visits
- Patients who have severe hearing impairments without access to assisted devices or programs to aid in listening to the recorded material
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Observational (audio recording)
Patients audio record the recommendations and instructions given to them by the doctor record as part of their clinic visit at the Supportive Care Center.
|
Ancillary studies
Audio record part of clinic visit
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients who will select "Complete Agree/Partially Agree" in Question 1 "I found the audio recording useful after the visit"
Time Frame: through study completion, an average of 1 year
|
Will be summarized using proportion along with a 95% confidence interval.
|
through study completion, an average of 1 year
|
Proportion of patients who will select "Complete Agree/Partially Agree" in Question 2 "I was able to effectively discuss my medical condition with my family member(s) and/or caregiver(s) who were not present at the clinical visit
Time Frame: through study completion, an average of 1 year
|
Will be summarized using proportion along with a 95% confidence interval.
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of times the recording is listened to
Time Frame: through study completion, an average of 1 year
|
Descriptive statistics will be used to summarize the results.
Wilcoxon rank sum test or Kruskal-Wallis test will be applied to examine differences in continuous variables between or among patient's demographic/clinical characteristics.
|
through study completion, an average of 1 year
|
To assess the ease of use of the technology.
Time Frame: through study completion, an average of 1 year
|
Descriptive statistics will be used to summarize the results.
Chi squared test or Fisher's exact test will be applied to examine the association between the ease of use of the technology and patient's demographic/clinical characteristics.
|
through study completion, an average of 1 year
|
To assess the ability to share the information with the patient's family member(s) and/or caregiver(s) if he or she chooses to do so.
Time Frame: through study completion, an average of 1 year
|
Descriptive statistics will be used to summarize the results.
Chi-squared test or Fisher's exact test will be applied to examine the association between the ability to share and patient's demographic/clinical characteristics.
|
through study completion, an average of 1 year
|
To assess the patient perception of whether the audio recording caused any disruption to the clinic
Time Frame: through study completion, an average of 1 year
|
Descriptive statistics will be used to summarize the results.
Chi-squared test or Fisher's exact test will be applied to examine the association between the patient perception of whether audio recording caused any disruption to the clinic and patient's demographic/clinical characteristics.
|
through study completion, an average of 1 year
|
Patient participation rate
Time Frame: through study completion, an average of 1 year
|
The participation rate of patients in this study will be estimate using proportion along with 95% confidence interval.
|
through study completion, an average of 1 year
|
To explore the association between the frequency of caregivers' use of audio recording
Time Frame: through study completion, an average of 1 year
|
Pearson or Spearman correlation coefficient will be used to assess the association between caregivers' age and frequency of their use of the audio recording.
Wilcoxon rank sum test will be applied to examine differences in frequency of caregivers' use of audio recording between their sexes.
|
through study completion, an average of 1 year
|
To explore the association of the ease of use of the technology and the type of device and application used
Time Frame: through study completion, an average of 1 year
|
Chi-squared test or Fisher's exact test will be applied to examine the association between the ease of use of the technology and the types of recording devices/applications.
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael J Tang, M.D. Anderson Cancer Center
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-0240 (Other Identifier: M D Anderson Cancer Center)
- NCI-2021-02621 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic and Lymphoid Cell Neoplasm
-
University of California, San FranciscoLazarex Cancer FoundationTerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant NeoplasmUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterWithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation